Program overview
Context
Indication: Lymphoma, Non-Hodgkin
Mechanism: Unknown
Modality: Unknown
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Low Signal
lisocabtagene maraleucel
lisocabtagene maraleucel is flagged as low signal because public records show limited public risk signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 1/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT03483103
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT03483103 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | strict_eligibility_signal |